13 October 2015 - PHARMAC is seeking feedback on a proposal involving levetiracetam and lamotrigine, resulting from a provisional agreement with Rex Medical Ltd. Both medicines are already listed in the Pharmaceutical Schedule in the Nervous System, Antiepilepsy Drugs, Therapeutic Group.

The proposal would result in:

• a reduction in expenditure for levetiracetam tablets;
• a new brand name for Levetiracetam-Rex (the brand name Levetiracetam-Rex will change to Everet);
• listing a new 1000 mg strength of levetiracetam tablet; and
• listing a new brand of lamotrigine dispersible tablets: 25 mg, 50 mg, and 100 mg (Motrig).

For more details, go to: http://www.pharmac.health.nz/news/new-news-page-5/